However, these results are consistent with preclinical data that suggest that loss of the growth inhibitory response to TGF-β signaling varies directly with the malignant stage of the tumor and the more aggressive forms actually switch to autocrine and/or paracrine growth stimulated by TGF-β. Here, TGFB1 is linked to neoplasm.